Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Doseology Sciences Inc. Capital/Financing Update 2026

May 19, 2026

48002_rns_2026-05-19_62033e2a-ad2f-499d-a01d-98dea3a1bb16.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Doseology Sciences Inc. (the "Company" or "Doseology")
Suite 305, 9-3151 Lakeshore Rd.
Kelowna, BC V1W 3S9

Item 2: Date of Material Change

April 28, 2026.

Item 3: News Release

A news release was issued May 15, 2026 and filed on SEDAR+ at www.sedarplus.ca.

Item 4: Summary of Material Changes

The Company announced that, further to its news release of March 30, 2026, it has received a 45-day extension from the Canadian Securities Exchange to close its non-brokered private placement (the "Offering"). See item 5 for further details.

Item 5: Full Description of Material Change

The Company announced that further to its news release of March 30, 2026, it has received a 45-day extension from the Canadian Securities Exchange to close its Offering. The Offering will consist of up to 3,225,806 units (each, a "Unit") at a price of $0.62 per Unit to raise aggregate gross proceeds of up to $2,000,000.

Additionally, the Company announced that Tim Corkum has resigned as the Company's President and COO effective April 28, 2026. The Company thanks Mr. Corkum for his contributions to the Company and wishes him well in his future endeavors.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

Not applicable.

Item 8: Executive Officer

For further information, please contact:

Chris Jackson, CEO
Email: [email protected]
Phone: 604.908.3095

Item 9: Date of Report

May 15, 2026.